A Win For Cyclerion Therapeutics, Inc.
Tue, Nov 22, 2022 at 07:25 PM
Cyclerion Therapeutics, Inc. (CYCN:NASDAQ) shot up at $0.75, representing a gain of 34.3%. On Tue, Nov 22, 2022, CYCN:NASDAQ hit a New 2-Week High of $0.75. The stock got featured on our News Catalysts scanner on Wed, Nov 09, 2022 at 07:38 AM in the 'EARNINGS' category. From Tue, Nov 08, 2022, the stock recorded 60.00% Up Days and 63.64% Green Days
About Cyclerion Therapeutics, Inc. (CYCN:NASDAQ)
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators.
Top 10 Gainers:
- Palisade Bio Inc. (PALI:NASDAQ), 81.08%
- Motorsport Games Inc. (MSGM:NASDAQ), 51.11%
- FOXO Technologies Inc. Class A (FOXO:NYSEMKT), 47.57%
- Cyclerion Therapeutics, Inc. (CYCN:NASDAQ), 34.31%
- XL Group Ltd (XL:NYSE), 30.91%
- Brainstorm Cell Therapeutics Inc. (BCLI:NASDAQ), 30%
- Digital Brands Group Inc. (DBGI:NASDAQ), 28.53%
- Ampio Pharmaceuticals, Inc. (AMPE:NYSEMKT), 28.32%
- Draganfly Inc. (DPRO:NASDAQ), 27.19%
- GH Research PLC (GHRS:NASDAQ), 25.86%